Published by Josh White on 11th November 2024
(Sharecast News) - Faron Pharmaceuticals, a clinical-stage biopharmaceutical company specialising in immunotherapies for cancer and inflammatory diseases, announced the filing of a new patent application for the use of soluble Clever-1 in targeting T-cell inactivation on Monday, with potential applications in treating autoimmune diseases and inflammatory disorders.